- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.02. | Following the Announcement of Its Proposed Merger With Erytech, Pherecydes Pharma Completes a €1.5 Million Capital Increase Reserved to Its Historical Shareholders | 701 | Business Wire | This capital increase, fully subscribed by Auriga IV Bioseeds, Ouest Ventures III and the pool of shareholders represented by Guy Rigaud, historical shareholders of Pherecydes Pharma, is part... ► Artikel lesen | |
| 16.02. | By merging with struggling Erytech, Pherecydes spies opportunity to boost AMR strategy | 4 | FierceBiotech | ||
| 16.02. | Pherecydes Pharma: ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies | 447 | Business Wire | Conference call and webcast in English on February 16, 2023 at 8:30am EST 02:30pm CET and in French on the same day at 12pm EST 6pm CET
Strategic combination would build on complementary expertise... ► Artikel lesen | |
| PHERECYDES PHARMA Aktie jetzt für 0€ handeln | |||||
| 15.02. | Erytech Pharma S.A.: ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies | 300 | GlobeNewswire (Europe) | ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies Conference call and webcast in English on February 16, 2023at 8:30am EST / 02:30pm... ► Artikel lesen | |
| 25.01. | Pherecydes Pharma Announces Its Participation in Several Scientific and Investor Conferences | 368 | Business Wire | Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial... ► Artikel lesen | |
| 03.01. | Pherecydes Pharma Announces its Financial Agenda for 2023 | 369 | Business Wire | Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announced... ► Artikel lesen | |
| 15.12.22 | Pherecydes Pharma: Minutes of the Combined General Meeting of December 15, 2022 | 382 | Business Wire | Adoption of all resolutions presented in line with the recommendations of the Board of Directors
Implementation of the separation of powers:
Thibaut du Fayet appointed Chief Executive... ► Artikel lesen | |
| 29.11.22 | Pherecydes Pharma Announces the Positive Recommendation of the DSMB For the Continuation of Its Phase II Clinical Study PhagoDAIR in Osteoarticular Infections Caused by Staphylococcus aureus | 314 | Business Wire | Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant... ► Artikel lesen | |
| 16.11.22 | Pherecydes Pharma Will Present Its Phagogram's Latest Progress During an Oral Session at the Phage Futures US 2022 Conference | 489 | Business Wire | Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant... ► Artikel lesen | |
| 27.10.22 | Pherecydes Pharma Publishes Its Half-Year 2022 Financial Results and Provides an Update on Its Development Plan | 456 | Business Wire | H1 2022 marked by the reaching of several key development milestones with anti-Staphylococcus aureus phages: Start of the PhagoDAIR Phase II clinical study in the treatment of osteoarticular... ► Artikel lesen | |
| 27.09.22 | Pherecydes Pharma Announces Its Participation in a Number of Major Scientific and Investor Conferences | 409 | Business Wire | Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces... ► Artikel lesen | |
| 22.09.22 | Pherecydes Pharma Successfully Completes €3.1 Million Capital Increase | 458 | Business Wire | Regulatory News:
Not for release, either directly or indirectly, in the United States, Canada, Australia or Japan. Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology company... ► Artikel lesen | |
| 21.09.22 | Pherecydes Pharma Launches a Capital Increase for c. €3m to Continue Its Clinical Development Program in Phage Therapy | 728 | Business Wire | Global Offering aimed at institutional investors, as well as individual investors via the PrimaryBid platform Subscription commitments totaling at least €2.3 million from longstanding shareholders... ► Artikel lesen | |
| 15.09.22 | Pherecydes Pharma Announces the Creation of an International Medical Advisory Board | 481 | Business Wire | This group of infectious diseases experts will contribute to the design and implementation of the Company's clinical development strategy in phage therapy
Regulatory News:
Pherecydes Pharma... ► Artikel lesen | |
| 12.09.22 | Pherecydes Pharma Announces a First Registration of Its Phagogram as an in Vitro Diagnostic Test in Accordance With EC Directives | 323 | Business Wire | This vital tool for precision medicine thus meets regulatory requirements and clinicians' expectations
Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology... ► Artikel lesen | |
| 27.06.22 | Pherecydes Pharma: Positive Preclinical Results for Inhaled Phage Therapy Presented to the Reanimation 2022 Conference | 342 | Business Wire | A preclinical study demonstrates the benefits of inhaled Pherecydes Pharma phages in treating ventilator-associated pneumonia
Regulatory News:
Pherecydes Pharma (Paris:ALPHE)(FR0011651694... ► Artikel lesen | |
| 15.06.22 | Pherecydes Pharma announces the enrollment of the first patient in the phase II study PhagoDAIR in the treatment of osteoarticular infections caused by Staphylococcus aureus | 315 | Business Wire | Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE), a biotech company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, announced... ► Artikel lesen | |
| 08.06.22 | Pherecydes Pharma Organizes a Scientific Symposium During the 23rd National Days of Infectiology | 504 | Business Wire | Phage therapy in 2022: French experience
Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE, PEA-PME eligible), a biotech company specializing in precision phage therapy to treat resistant... ► Artikel lesen | |
| 30.05.22 | Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages | 432 | Business Wire | This is the first AAC for a treatment in patients who have failed antibiotic therapy, particularly expected in the context of the fight against antibiotic resistance.
Regulatory News:
Pherecydes... ► Artikel lesen | |
| 23.05.22 | The General Assembly of Pherecydes Pharma Approves the Evolution of Its Governance Towards a Company with a Board of Directors | 389 | Business Wire | The new Board of Directors has appointed Didier Hoch as Chairman and CEO, and Thibaut du Fayet as Deputy CEO
Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE, éligible PEA-PME) (Paris:ALPHE)... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 125,35 | +1,17 % | Laufende Fusionskontrollverfahren: BioNTech SE, Mainz (Athos KG, Holzkirchen); Erwerb aller Geschäftsanteile und Kontrolle über InstaDeep Ltd, London /UK | Datum der Anmeldung:14.03.2023Aktenzeichen:B3-42/23Unternehmen:BioNTech SE, Mainz (Athos KG, Holzkirchen); Erwerb aller Geschäftsanteile und Kontrolle über InstaDeep Ltd, London/UKProduktmärkte:Entwicklung... ► Artikel lesen | |
| BB BIOTECH | 52,60 | -0,75 % | Biotech Report: Biotest und BB Biotech behauptet, MorphoSys tiefrot | (shareribs.com) Frankfurt / New York 17.03.2023 - Biotech-Aktien zeigten sich im deutschen Handel überwiegend leichter. MorphoSys gaben nach, während Biotest und BB Biotech zulegen konnten. Auch an... ► Artikel lesen | |
| QIAGEN | 42,820 | +0,14 % | Biotech Report: Sektor unter Druck - MorphoSys vor Zahlen tiefrot, Qiagen behauptet | (shareribs.com) Frankfurt / New York 15.03.2023 - Biotech-Aktien zeigten sich im deutschen Handel teils deutlich leichter und konnten sich dem Marktdruck nicht entziehen. Auch an der Wall Street verlor... ► Artikel lesen | |
| PAION | 0,639 | -1,24 % | EQS-News: PAION AG: PAION veranstaltet gesponsertes Angiotensin-II-Symposium auf dem ISICEM in Brüssel | EQS-News: PAION AG
/ Schlagwort(e): Konferenz
PAION VERANSTALTET GESPONSERTES ANGIOTENSIN-II-SYMPOSIUM AUF DEM ISICEM IN BRÜSSEL
16.03.2023 / 10:00 CET/CEST
Für... ► Artikel lesen | |
| AMGEN | 212,30 | +0,07 % | Unser Robot zum Dow: Am Mittwoch in Richtung Jahreslow, Amgen stark | Der Dow Jones verlor am Mittwoch -0,87% auf 31874,57 Punkte. Year-to-date liegt der Dow Jones nun 3,84% im Minus. Es gab bisher 21 Gewinntage und 21 Verlusttage. Auf das Jahreshoch fehlen 7,08%, vom... ► Artikel lesen | |
| EPIGENOMICS | 0,720 | +4,35 % | XETR DE000A32VN83: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME Waehrung/Currency ISIN BIS/UNTILEPIGENOMICS AG NA... ► Artikel lesen | |
| BIOGEN | 238,50 | -1,30 % | Biogen Updates On FDA Advisory Committee Meeting On Tofersen For SOD1-ALS | WESTON (dpa-AFX) - Biotechnology company Biogen Inc. (BIIB) announced the outcome of the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee meeting... ► Artikel lesen | |
| NANOREPRO | 1,902 | -0,42 % | Im deutschen Small Cap-Bereich gibt es bei NANOREPRO eine Anomalie | Ca. 33 Mio. € Nettocash stehen gegen 25,5 Mio. € Börsenwert und geschätzt 10 bis 12 Mio. € knapp profitablen Umsatz mit diagnostischen Selbsttests. Bis Jahresende ist der Ausbau dieser Cashposition... ► Artikel lesen | |
| ILLUMINA | 200,40 | +0,22 % | Illumina: Icahn's Director Nominees Do Not Add Value To Board | SAN DIEGO (dpa-AFX) - Illumina (ILMN) issued a response to Carl Icahn's public statements and letters to the company's shareholders. Illumina said its Nominating/Corporate Governance Committee... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 717,00 | +3,70 % | Sanofi And Regeneron Say Phase 3 Study Of Dupixent To Treat COPD Meets Endpoints | PARIS (dpa-AFX) - Sanofi S.A. (SNYNF) and Regeneron Pharmaceuticals, Inc. (REGN) on Thursday said late-stage study of their Dupixent for the treatment of chronic obstructive pulmonary disease... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,000 | -0,99 % | Expert Ratings for CRISPR Therapeutics | ||
| SANGAMO THERAPEUTICS | 1,646 | +1,27 % | SGMO Stock: $15 Price Target Received | ||
| EDITAS MEDICINE | 7,148 | +5,10 % | Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates | Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter On track to provide clinical update for RUBY trial by mid-2023 and... ► Artikel lesen | |
| AMYRIS | 1,225 | +0,39 % | Amyris, Inc. (AMRS) Q4 2022 Earnings Call Transcript | ||
| INTELLIA THERAPEUTICS | 34,730 | +0,59 % | Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
